Given that PI3K/AKT/mTOR signaling was activated in RCC patients, rapalogues were FDA approved for use in the clinic, however, these agents showed tumor regression in a minority of patients with the development of resistance being a major limitation of therapy. Here, MTOR is linked to renal cell carcinoma.